Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours

NCT04808362 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
22
Enrollment
INDUSTRY
Sponsor class

Stopped Phase 1completed; sponsor decided to change strategy to a combination study

Conditions

Interventions

Sponsor

Peptomyc S.L.